Latest Breaking News On - Efficacy results - Page 1 : vimarsana.com

G1 Therapeutics Announces Upcoming Presentation at the 2024

G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting.

United statesAmerican society of clinical oncologyResearch triangle parkExchange commissionCorporate communicationsTherapeutics incClinical oncologyPresentation detailsSacituzumab govitecanMetastatic triple negative breast cancerUpdated phaseEfficacy resultsPrivate securities litigation reform actInvestor relations

G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting

RESEARCH TRIANGLE PARK, N.C., May 23, 2024 G1 Therapeutics, Inc. , a commercial-stage oncology company, today announced that mature Phase 2 results describing the positive impact of trilaciclib.

United statesTherapeutics incAmerican society of clinical oncologyExchange commissionResearch triangle parkCorporate communicationsClinical oncologyPresentation detailsSacituzumab govitecanMetastatic triple negative breast cancerUpdated phaseEfficacy resultsPrivate securities litigation reform actInvestor relations

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

MALVERN, Pa., May 20, 2024 Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun.

British columbiaTarun upadhyayExchange commissionInternational society for cell gene therapyVancouver convention centreOcugen incHead of research developmentHead of communicationsChief scientific officerInternational societyGene therapyAnnual meetingBreaking oral abstract sessionEfficacy resultsPoster networking sessionPrivate securities litigation reform act

BioInvent to Present Additional Promising Phase 1/2a Data at EHA 2024

BioInvent to Present Additional Promising Phase 1/2a Data at EHA 2024
pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.

Hodgkin lymphomaabstractMartin welschofCecilia hofvanderBioinvent international ab nasdaq stockholmNews networkBioinvent internationalEuropean hematology associationNasdaq stockholmChief executive officerEfficacy resultsSenior director investor relationsphone

BioInvent International: BioInvent to Present Additional Promising Phase 1/2a Data at EHA 2024 for BI-1206 with rituximab in NHL

BioInvent International: BioInvent to Present Additional Promising Phase 1/2a Data at EHA 2024 for BI-1206 with rituximab in NHL
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Cecilia hofvanderMartin welschofEuropean hematology associationBioinvent international ab nasdaq stockholmBioinvent internationalNasdaq stockholmChief executive officerEfficacy resultsSenior director investorPresent additional promising phaseChance des